Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 14/20 | 0.51 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23491959 | 1.00 | MCL1 (0.51) | MCL1P2RX3ABCB1FKBP1ABCL2 | |
| SCHEMBL12742659 | 1.00 | MCL1 (0.51) | MCL1P2RX3ABCB1FKBP1ABCL2 | |
| SCHEMBL6974007 | 1.00 | MCL1 (0.51) | MCL1P2RX3ABCB1FKBP1ABCL2 | |
| SCHEMBL23491353 | 0.93 | MCL1 (0.54) | MCL1P2RX3BCL2 | |
| SCHEMBL15888149 | 0.92 | MCL1 (0.49) | MCL1P2RX3ABCB1BCL2 | |
| SCHEMBL5963763 | 0.90 | MCL1 (0.54) | MCL1BCL2 | |
| SCHEMBL1448111 | 0.89 | ABCB1 (0.54) | MCL1ABCB1FKBP1A | |
| SCHEMBL7703700 | 0.89 | ABCB1 (0.54) | MCL1ABCB1FKBP1A | |
| SCHEMBL21273903 | 0.89 | ABCB1 (0.54) | MCL1ABCB1FKBP1A | |
| SCHEMBL7279798 | 0.89 | ABCB1 (0.54) | MCL1ABCB1FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062007-B2 | Cyclic amide BACE-1 inhibitors having a benzamide substituent | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9062007-B2 | Cyclic amide BACE-1 inhibitors having a benzamide substituent | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140128361-A1 | CYCLIC AMIDE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128361-A1 | CYCLIC AMIDE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8623867-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-8623867-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130004518-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | Merck, Sharp & Dohme Corp. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8278334-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | Merck, Sharp & Dohme Corp. (US) | 2012-10-02 | — | — | US | disclosed |
| US-8278334-B2 | Cyclic amine BACE-1 inhibitors having a benzamide substituent | Merck, Sharp & Dohme Corp. (US) | 2012-10-02 | — | — | US | disclosed |
| US-7910590-B2 | Cyclic amine bace-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION | 2009-12-17 | — | — | US | disclosed |
| US-7598250-B2 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| EP-1660443-B1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORP (US) | 2009-03-04 | — | — | EP | disclosed |
| EP-1660447-B1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1660447-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660443-A2 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORPORATION (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050119227-A1 | Cyclic amine bace-1 inhibitors having a benzamide substituent | SCHERING CORPORATION | 2005-06-02 | — | — | US | disclosed |
| WO-2005016876-A2 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050043290-A1 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | SCHERING CORPORATION AND PHARMACOPEIA DRUG DISCOVERY INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005014540-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128361-A1 | CYCLIC AMIDE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | BACE1, BACE2, BCHE | MCL1 3050/4885P2RX3 2982/4885ABCB1 270/4885 |
| US-20050043290-A1 | Cyclic amine BACE-1 inhibitors having a heterocyclic substituent | BACE1, BACE2, PSEN1 | MCL1 1824/4885P2RX3 2056/4885ABCB1 301/4885 |
| US-20050119227-A1 | Cyclic amine bace-1 inhibitors having a benzamide substituent | BACE1, BACE2, BCHE | MCL1 3107/4885P2RX3 2875/4885ABCB1 236/4885 |
| US-20130004518-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT | BACE1, BACE2, BCHE | MCL1 3107/4885P2RX3 2875/4885ABCB1 236/4885 |
| US-20090312341-A1 | CYCLIC AMINE BACE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | BACE1, BACE2, PSEN1 | MCL1 1824/4885P2RX3 2056/4885ABCB1 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.